Synthetech Inc fka NZYM

[Knowledge is King]

NZYM looking at "strategic alternatives"


With a book value of $.70+ and peak earnings power of perhaps $.15/share, I'd say NZYM could, in a buyout, fetch quite a bit more than the current $.60 stock price.


PRW: Synthetech Announces Engagement of Financial Advisor to Evaluate Strategic
Alternatives

ALBANY, Ore., June 28 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC
Bulletin Board: NZYM) today announced that it has engaged Brocair Partners,
LLC to conduct a comprehensive review of strategic alternatives aimed at
enhancing shareholder value. Strategic alternatives Synthetech may pursue
could include, among others, execution of Synthetech's operating plan, the
sale or acquisition of assets or businesses, partnering or other
collaboration agreements or arrangements, a merger or sale of the company or
other strategic transactions. The exploration of strategic alternatives may
not result in any agreement or transaction and, if completed, any agreement
or transaction may not be successful or on attractive terms. Synthetech does
not intend to disclose developments with respect to this process unless and
until the evaluation of strategic alternatives has been completed or it
enters into definitive agreements for a specific, material transaction.
About Synthetech
Synthetech, Inc., based in Albany, Oregon, is a fine chemicals company
specializing in organic synthesis, biocatalysis and chiral technologies.
Synthetech develops and manufactures amino acid derivatives, specialty amino
acids, peptide fragments and proprietary custom chiral intermediates
primarily for the pharmaceutical industry. Synthetech produces advanced
pharmaceutical intermediates in accordance with current Good Manufacturing
Practices (cGMP) in compliance with U.S. Food and Drug Administration (FDA)
regulations. Synthetech's products support the development and manufacture
of therapeutic peptides and peptidomimetic (peptide-like) small molecule
drugs from early stages of a customer's clinical development through market
launch and into commercial production. Synthetech's products also support
the production of chemically-based medical devices. Synthetech's domestic
and international customer base includes major and mid-size pharmaceutical,
contract drug synthesis, emerging and established biotechnology and medical
device companies. Synthetech also supplies catalog quantities of specialty
amino acids to research institutions, universities and drug discovery firms.


MORE INFORMATION:
Web site: www.synthetech.com
E-mail: [e-mail]

CONTACT:
Gary Weber, CFO
PO Box 646 Albany, Oregon 97321
541 967-6575


SOURCE Synthetech, Inc.
/CONTACT: Gary Weber, CFO of Synthetech, Inc., [phone]
/Web site: http://www.synthetech.com